版本:
中国

BRIEF-Amgen announces positive top line results from Phase 3 GLAGOV imaging study of Repatha(evolocumab)

Sept 20 Amgen

* Intravascular ultrasound study meets primary and secondary endpoints

* Announces positive top line results from phase 3 GLAGOV imaging study of Repatha (evolocumab) Source text for Eikon:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐